Vancomycin-Resistant Enterococcus in Critical Care Areas

Critical Care Nursing Clinics of North America

Volumn 19, Issue 1, 2007, Pages 69-75

  Bryant, Sharon ^a,b   Wilbeck, Jennifer ^a,c  

^a VANDERBILT UNIVERSITY SCHOOL OF NURSING   (United States)

^b Kindred Hospital   (United States)

^c CENTENNIAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CROSS INFECTION; DRUG EFFECT; ENTEROCOCCUS; GENETIC PREDISPOSITION; HUMAN; INTENSIVE CARE; POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR;

CRITICAL CARE; CROSS INFECTION; ENTEROCOCCUS; GENETIC PREDISPOSITION TO DISEASE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; POLYMERASE CHAIN REACTION; RISK FACTORS; VANCOMYCIN RESISTANCE;

EID: 33847263472     PISSN: 08995885     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccell.2006.10.005     Document Type: Review

References (35)

1. Aragon D., Sole M.L., and Brown S. Outcomes of an infection prevention project focusing on hand hygiene and isolation practices. AACN Clin Issues 16 2 (2005) 121-132
2. Diekema D.J., BootsMiller B.J., Vaughn T.E., et al. Antimicrobial resistance trends and outbreak frequency in United States hospitals. CID 38 (2004) 78-85
3. Puzniak L.A., Gillespie K.N., Leet T., et al. A cost benefit analysis of gown use in controlling vancomycin resistant Enterococcus transmission: is it worth the price. Infect Control Hosp Epidemiol 25 5 (2004) 418-424
4. de Piero M., Yarnold P.R., Warren J., et al. Risk factors and outcomes associated with non-Enterococcus faecalis, non-Enterococcus faecium enterococcal bacteremia. Infect Control Hosp Epidemiol 27 1 (2006) 28-33
5. Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, US Department of Health and Human Services. National Nosocomial Infections Surveillance (NNIS) Systems report: data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 31 (2003) 481-498
6. Raad I.I., Hend H.A., Boktour M., et al. Vancomycin resistant Enterococcus faecium: catheter colonization, van gene and decreased susceptibility to antibiotics in biofilm. Antimicrob Agents Chemother 49 12 (2005) 5046-5050
7. DeLisle S., and Pel T.M. Conundrums in the management of critically ill patients. Chest 123 5 (2003) 504S-518S
8. Zirakzadeh A., and Patel R. Vancomycin-resistant enterococci: colonization, infection, detection and treatment. Mayo Clin Proc 81 4 (2006) 529-536
9. Kauffman C.A. Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections. J Antimicrob Chemother 51 Suppl S3 (2003) iii23-iii30
10. Lodise T.P., McKinnin P.S., Tam V.H., et al. Clinical outcomes for patients with bacteremia caused by vancomycin resistant enterococcus in a level 1 trauma center. CID 34 (2002) 922-929
11. Salgado C.D., O'Grady N., Farr B.M., et al. Prevention and control of antimicrobial-resistant infections in intensive care patients. Crit Care Med 33 10 (2005) 2373-2382
12. Silveira F., Fujitani S., Paterson D.L., et al. Antibiotic-resistant infections in the critically ill adult. Clin Lab Med 24 (2004) 329-341
13. Wong M.T., Kauffman C.A., Standiford H.C., et al. Effective suppression of vancomycin-resistant enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. CID 33 (2001) 1476-1482
14. Raad I.I., Darouiche R., Haechem M., et al. Antibiotic colonization of catheters. Antimicrob Agents Chemother 39 (1995) 2397-2400
15. Ramadhan A.A., and Hegedus E. Survivability of vancomycin resistant enterococci and fitness cost of vancomycin resistance acquisition. J Clin Pathol 58 7 (2005) 744-746
16. Ramadhan A.A., and Hedegus E. Biofilm production and esp gene carriage in enterococci. J Clin Pathol 58 7 (2005) 685-686
17. Levinson W., and Jawetz E. Medical microbiology & immuniology (1998), Appleton & Lange, (CT) p. 62-69
18. Polgreen P.M., Beekman S.E., Chen Y.Y., et al. Epidemiology of methicillin resistant Staphylococcus aureus and vancomycin resistant Enterococcus in a rural state. Infect Control Hosp Epidemiol 27 3 (2006) 252-256
19. Raad I.I., Hanna H., Boktour, et al. Catheter-related vancomycin resistant Enterococcus faecium bacteremia: clinical and molecular epidemiology. Infect Control Hosp Epidemiol 26 7 (2005) 658-661
20. Konegaard R, Myers F, Edward C. Arresting drug resistant organisms. Nursing 2005;35(6):48-50.
21. Raad II, Hanna HA, Chaiban G, et al. The presence of the esp gene bioprosthetic colonization, and DNA restriction pattern in vancomycin-resistant Enterococcus faecium (VREF) causing catheter-related bacteremia (CRB). Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago (IL), September 14-17, 2003.
22. Domingo M.-C., Huletsky A., Giroux R., et al. High prevalence of glycopeptide resistant genes vanB, vanD, and vanG not associated with enterococci in human fecal flora. Antimicrob Agents Chemother 49 11 (2005) 4784-4786
23. Landman D., and Quale J.M. Management of infections due to resistant enterococci: a review of therapeutic options. J Antimicrob Chemother 40 (1997) 161-170
24. Patel R. Clinical impact of vancomycin-resistant enterococci. J Antimicrob Chemother 51 Suppl S3 (2003) iii13-iii21
25. Birmingham M.C., Rayner C.R., Meagher A.K., et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. CID 36 (2003) 159-168
26. Babcock H.M., Ritchie D.J., Christiansen E., et al. Successful treatment of vancomycin-resistant enterococcus endocarditis with oral linezolid. CID 32 (2001) 1373-1375
27. Chien J.W., Kucia M.L., Salata R.A., et al. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. CID 30 (2000) 146-151
28. Gonzales R.D., Schreckenberger P.C., Graham F.R., et al. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357 (2001) 1179
29. Herrero I.A., Issa N.C., Patel R., et al. Nosocomial spread of linezolid-resistant, vancomycin resistant, vancomycin Enterococcus faecium. N Engl J Med 346 (2002) 867-869
30. Maragakis L.L., Bradley K.L., Song X., et al. Increased catheter related bloodstream infection rates after the introduction of a new mechanical valve intravenous access port. Infect Control Hosp Epidemiol 27 1 (2006) 67-70
31. Austin D.J., Bonten J.M., Weinstein R.A., et al. Vancomycin-resistant enterococci in intensive-care hospital settings: transmission dynamics, persistence, and the impact of infection control programs. Proc Natl Acad Sci U S A 96 (1999) 6908-6913
32. Vernon M.O., Hayden M.K., Trick W.E., et al. Chlorhexidine gluconate to cleanse patients in a medical intensive care unit: the effectiveness of source control to reduce the bioburden of vancomycin resistant enterococci. Arch Intern Med 166 3 (2006) 306-312
33. Duckro A.N., Blom D.W., Lyle E.A., et al. Transfer of vancomycin resistant enterococci via health care worker hands. Arch Intern Med 165 3 (2005) 302-307
34. Stosor V., Peterson L.R., Postelnick M., et al. Enterococcus faecium bacteremia: does vancomycin resistance make a difference?. Arch Intern Med 158 (1998) 522-527
35. Song X., et al. Effect of nosocomial vancomycin resistant enterococcal bacteremia on mortality, length of stay and costs. Infect Control Hosp Epidemiol 24 (2003) 251-256